http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013229416-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49fa405631d8b7237cb0c75c8bd95404 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2013-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf934e48a8ed767f2a98b531b8bc3913 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c079f28e5c434faebd57419f3dab725c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70ca12eb435fe09909408635b7d2f5f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a473cfee604b706eb5037824473bccee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eb81b72a223b329d45d9103696aabc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_372dc69d2f0f4c90649fcdb957a262bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc231d2e89dee93e0e0762333a36aeb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61d3f9908a5dda0c043698e54959ad3e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_651e9822c0f7fb72443808072a608330 |
| publicationDate | 2014-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2013229416-A1 |
| titleOfInvention | miRNA based treatment monitoring in multiple sclerosis |
| abstract | The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient. Further, the present invention relates to the use of a polynucleotide or a polynucleotide set for detecting a miRNA to determine whether a patient responds to a therapeutic treatment of multiple sclerosis, to monitor the course of multiple sclerosis in a patient, to determine the risk of a relapse of multiple sclerosis in a patient, to adjust the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, and to identify a compound suitable for the treatment of multiple sclerosis in a patient. Furthermore, the present invention relates to a kit for determining whether a patient responds to a therapeutic treatment of multiple sclerosis, for monitoring the course of multiple sclerosis in a patient, for determining the risk of a relapse of multiple sclerosis in a patient, for adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, or for identifying a compound suitable for the treatment of multiple sclerosis in a patient comprising means for determining the level of at least one miRNA in a test sample isolated from a patient. |
| priorityDate | 2012-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 113.